Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in rare and ultra-rare disease therapies, has announced an inducement grant of 113,572 restricted stock units to 33 newly hired non-executive officers. The grants, approved by the company's compensation committee, were made under the Ultragenyx Employment Inducement Plan on August 16, 2025.
The restricted stock units will vest over a four-year period, with 25% of shares vesting annually on each grant date anniversary, contingent on continuous employment.
[]Ultragenyx Pharmaceutical (NASDAQ: RARE), azienda biofarmaceutica specializzata in terapie per malattie rare e ultra-rare, ha comunicato l'assegnazione a titolo d'incentivo di 113.572 unit脿 azionarie vincolate a 33 dirigenti non esecutivi recentemente assunti. Le assegnazioni, approvate dal comitato per le retribuzioni, sono state effettuate ai sensi dell'Ultragenyx Employment Inducement Plan in data 16 agosto 2025.
Le unit脿 azionarie vincolate matureranno in un periodo di quattro anni, con il 25% delle azioni che diventer脿 disponibile ogni anniversario della data di assegnazione, subordinatamente alla continua relazione di lavoro.
Ultragenyx Pharmaceutical (NASDAQ: RARE), una compa帽铆a biofarmac茅utica especializada en terapias para enfermedades raras y ultrarraras, anunci贸 una concesi贸n por inducimiento de 113.572 unidades restringidas de acciones a 33 nuevos directivos no ejecutivos. Las concesiones, aprobadas por el comit茅 de compensaci贸n de la empresa, se realizaron bajo el Ultragenyx Employment Inducement Plan el 16 de agosto de 2025.
Las unidades restringidas de acciones se devengar谩n a lo largo de un periodo de cuatro a帽os, con el 25% de las acciones que se adquirir谩 cada aniversario de la fecha de concesi贸n, condicionado a la continuidad del empleo.
Ultragenyx Pharmaceutical (NASDAQ: RARE), 頋穩 氚� 齑堩潿攴� 歆堩櫂 旃橂鞝滌棎 韸鬼檾霅� 氚旍澊鞓れ牅鞎巾殞靷澑 鞚� 須岇偓電� 33氇呾潣 鞁犾瀰 牍勳瀯鞗� 鞛勳洂鞐愱矊 鞙犾澑 氤挫儊鞙茧 113,572臧滌潣 鞝滍暅攵� 欤检嫕 雼渼(RSU)毳� 攵�鞐枅雼り碃 氚滍憸頄堨姷雼堧嫟. 頃措嫻 攵�鞐姅 須岇偓 氤挫儊鞙勳洂須岇潣 鞀轨澑鞚� 氚涭晞 2025雲� 8鞗� 16鞚� Ultragenyx Employment Inducement Plan鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�.
鞚� 鞝滍暅攵� 欤检嫕 雼渼電� 4云勱皠鞐� 瓯胳硱 臧�靻嶋悩氅�, 攵�鞐澕 旮办 毵る厔 旮半厫鞚茧雼� 鞝勳泊鞚� 25%臧� 氩犾姢韺呺悩氅� 瓿勳啀 瓿犾毄 靸來儨臧� 鞙犾霅橃柎鞎� 頃╇媹雼�.
Ultragenyx Pharmaceutical (NASDAQ: RARE), une soci茅t茅 biopharmaceutique sp茅cialis茅e dans les traitements des maladies rares et ultra-rares, a annonc茅 l'attribution 脿 titre d'incitation de 113 572 unit茅s d'actions restreintes 脿 33 nouveaux cadres non dirigeants. Les attributions, approuv茅es par le comit茅 de r茅mun茅ration de la soci茅t茅, ont 茅t茅 effectu茅es dans le cadre de l'Ultragenyx Employment Inducement Plan le 16 ao没t 2025.
Les unit茅s d'actions restreintes seront acquises sur une p茅riode de quatre ans, 25 % des actions devenant acquises chaque ann茅e 脿 la date anniversaire de l'attribution, sous r茅serve de la continuit茅 de l'emploi.
Ultragenyx Pharmaceutical (NASDAQ: RARE), ein biopharmazeutisches Unternehmen, das sich auf Therapien f眉r seltene und ultraseltende Krankheiten spezialisiert hat, gab die Gew盲hrung von 113.572 Restricted Stock Units als Anreiz f眉r 33 neu eingestellte nichtgesch盲ftsf眉hrende F眉hrungskr盲fte bekannt. Die Gew盲hrungen wurden vom Verg眉tungsausschuss des Unternehmens genehmigt und am 16. August 2025 im Rahmen des Ultragenyx Employment Inducement Plan vorgenommen.
Die Restricted Stock Units werden 眉ber einen Zeitraum von vier Jahren vesten, wobei jeweils 25 % der Aktien an jedem Jahrestag des Zuteilungsdatums freigegeben werden, vorbehaltlich der fortgesetzten Besch盲ftigung.
- None.
- None.
NOVATO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 113,572 restricted stock units of the company鈥檚 common stock to 33 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company鈥檚 board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of August 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx鈥檚 strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: .
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
FAQ
How many restricted stock units did Ultragenyx (RARE) grant to new employees in August 2025?
What is the vesting schedule for Ultragenyx's (RARE) August 2025 inducement grants?
How many new non-executive employees received Ultragenyx (RARE) stock grants in August 2025?
Under what regulation were Ultragenyx's (RARE) August 2025 employee stock grants made?
